The efficacy of using FGF21-164 to reduce hepatic fat accumulation in DIO mice suggested that it may help treat non-alcoholic fatty liver disease (NAFLD). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.